Willems, Laurent M. http://orcid.org/0000-0001-8226-1674
Hamer, Hajo M.
Knake, Susanne
Rosenow, Felix
Reese, Jens-Peter
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Article History
First Online: 3 June 2019
Compliance with Ethical Standards
:
: This study was supported by the LOEWE Grant for the “Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany.
: LM. Willems and J.P. Reese report no conflicts of interest. H.M. Hamer has served on the scientific advisory board of Cerbomed, Desitin, Eisai, GW, Novartis, and UCB Pharma. He served on the speakers’ bureau of or received unrestricted grants from Amgen, Ad-Tech, Bial, Bracco, Cyberonics, Desitin, Eisai, Hexal, Nihon Kohden, Novartis, Pfizer, and UCB Pharma. S. Knake reports honoraria for speaking engagements from Desitin and UCB as well as educational grants from AD Tech, Desitin Arzneimittel, Eisai, GW, Medtronic, Novartis, Siemens and UCB. F. Rosenow reports personal fees from Eisai, grants and personal fees from UCB, grants and personal fees from Desitin Pharma, personal fees and others from Novartis, personal fees from Medronic, personal fees from Cerbomed, personal fees from ViroPharma and Shire, grants from the European Union, and grants from the Deutsche Forschungsgemeinschaft. A. Strzelczyk reports personal fees and grants from Desitin Arzneimittel, Eisai, GW Pharma, LivaNova, Medtronic, Sage Therapeutics, UCB Pharma, and Zogenix. All authors confirm that they have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.